Obsessive–compulsive disorder

NOCD Funds Actuarial Study to Reveal Social, Clinical, and Financial Impact of OCD

Monday, May 10, 2021 - 2:37pm

Interested parties should register for the event now and plan to attend the session titled OCD Prevalence and Outcomes.

Key Points: 
  • Interested parties should register for the event now and plan to attend the session titled OCD Prevalence and Outcomes.
  • We help people reclaim their lives with clinically proven OCD treatment, by removing barriers to OCD care, and by reducing the stigma associated with OCD.
  • Working together with our therapists, patients, health plans, providers, and employers, we are improving the lives of people with OCD.
  • Please visit our website for more information about NOCD.\n* Certain data used in this study were supplied by International Business Machines Corporation (IBM).

Correction Notice to Press Release Announcing Expansion of nView Health Behavioral Health Solutions Portfolio

Friday, May 7, 2021 - 2:30pm

b'ATLANTA, May 7, 2021 /PRNewswire-PRWeb/ --nView Health announced today a correction to its press release issued on April 14, 2021, announcing expansion of its solutions portfolio to include the world\'s leading Obsessive Compulsive Disorder Measurements.\nThe press release stated that nView was "the worldwide exclusive owner and provider of the Mini International Neuropsychiatric Interview (the M.I.N.I.

Key Points: 
  • b'ATLANTA, May 7, 2021 /PRNewswire-PRWeb/ --nView Health announced today a correction to its press release issued on April 14, 2021, announcing expansion of its solutions portfolio to include the world\'s leading Obsessive Compulsive Disorder Measurements.\nThe press release stated that nView was "the worldwide exclusive owner and provider of the Mini International Neuropsychiatric Interview (the M.I.N.I.
  • KID for Children and Adolescents, and the entire portfolio of Sheehan Technology."
  • nView is the worldwide exclusive licensee as well as an owner for a broad array of behavioral health screening solutions, structured interviews, and post-diagnosis severity measurement scales to monitor patient outcomes.
  • To learn more, please visit nview.com or follow nView on LinkedIn or Twitter .\n'

Greenbrook TMS Announces Preliminary First Quarter 2021 Operational and Financial Results

Tuesday, May 4, 2021 - 9:46pm

b'Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (\xe2\x80\x9cGreenbrook\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d) today announced certain preliminary unaudited operational and financial results for the first quarter ended March 31, 2021 (\xe2\x80\x9cQ1 2021\xe2\x80\x9d).

Key Points: 
  • b'Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (\xe2\x80\x9cGreenbrook\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d) today announced certain preliminary unaudited operational and financial results for the first quarter ended March 31, 2021 (\xe2\x80\x9cQ1 2021\xe2\x80\x9d).
  • We are proud of our team\xe2\x80\x99s efforts to continue to treat patients suffering from treatment resistant depression and obsessive-compulsive disorder during this difficult time.
  • TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation.
  • In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information.

BrainsWay Announces Launch of Noninvasive Treatment for Smoking Addiction to U.S. Providers

Thursday, April 29, 2021 - 2:03pm

b'For more information on Deep TMS treatment for smoking addiction, visit www.brainsway.com .\nBrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.

Key Points: 
  • b'For more information on Deep TMS treatment for smoking addiction, visit www.brainsway.com .\nBrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.
  • The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives.
  • BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy.
  • Current indications include major depressive disorder, obsessive-compulsive disorder, and smoking addiction.

Tridiuum and NOCD Partner to Diagnose OCD Patients Faster and Accelerate Access to Clinically Proven Treatment

Wednesday, April 28, 2021 - 1:38pm

The new partnership focuses on identifying more patients with OCD to diagnose them correctly faster and with less effort.

Key Points: 
  • The new partnership focuses on identifying more patients with OCD to diagnose them correctly faster and with less effort.
  • For payers and providers this often results in a hidden population of complex OCD patients with high levels of unnecessary utilization and poor outcomes.
  • It is proven to identify behavioral conditions faster, accelerate access to care, engage patients, and deliver vital treatment progress tracking.
  • We help people reclaim their lives with clinically proven OCD treatment, by removing barriers to OCD care, and by reducing the stigma associated with OCD.

MagVenture receives CE approvals for noninvasive brain treatment of addiction, OCD, and depression with anxiety symptoms

Wednesday, April 28, 2021 - 9:00am

b'COPENHAGEN, Denmark, April 28, 2021 /PRNewswire/ -- Global MedTech pioneer MagVenture has received CE approval for the treatment of addiction and Obsessive-Compulsive Disorder (OCD).

Key Points: 
  • b'COPENHAGEN, Denmark, April 28, 2021 /PRNewswire/ -- Global MedTech pioneer MagVenture has received CE approval for the treatment of addiction and Obsessive-Compulsive Disorder (OCD).
  • In addition, MagVenture TMS Therapy can reduce the symptoms of comorbid anxiety in patients suffering from depression.
  • "\nFor OCD, a 45% response rate was reported for the group receiving treatment, compared to 18% in the sham group.
  • "\nFor subjects responding to the treatment of MDD, who have symptoms of comorbid anxiety, the clinical benefit can additionally include an improvement of anxiety symptoms.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/magventure-receives-ce-approvals...\n'

MagVenture receives CE approvals for noninvasive brain treatment of addiction, OCD, and depression with anxiety symptoms

Wednesday, April 28, 2021 - 9:00am

b'COPENHAGEN, Denmark, April 28, 2021 /PRNewswire/ -- Global MedTech pioneer MagVenture has received CE approval for the treatment of addiction and Obsessive-Compulsive Disorder (OCD).

Key Points: 
  • b'COPENHAGEN, Denmark, April 28, 2021 /PRNewswire/ -- Global MedTech pioneer MagVenture has received CE approval for the treatment of addiction and Obsessive-Compulsive Disorder (OCD).
  • In addition, MagVenture TMS Therapy can reduce the symptoms of comorbid anxiety in patients suffering from depression.
  • "\nFor OCD, a 45% response rate was reported for the group receiving treatment, compared to 18% in the sham group.
  • "\nFor subjects responding to the treatment of MDD, who have symptoms of comorbid anxiety, the clinical benefit can additionally include an improvement of anxiety symptoms.\n'

BrainsWay Receives FDA Clearance for Three-Minute Theta Burst Treatment Protocol for Major Depressive Disorder

Monday, April 26, 2021 - 12:30pm

\xe2\x80\x9cThis protocol shows that innovation need not be revolutionary or radical to have a positive effect on peoples\xe2\x80\x99 lives.

Key Points: 
  • \xe2\x80\x9cThis protocol shows that innovation need not be revolutionary or radical to have a positive effect on peoples\xe2\x80\x99 lives.
  • BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy.
  • Current indications include major depressive disorder, obsessive-compulsive disorder, and smoking addiction.
  • Founded in 2003, with offices in Cresskill, NJ and Jerusalem, Israel, BrainsWay is committed to increasing global awareness and broad access to Deep TMS.

nView Health Announces Expansion of Behavioral Health Solutions Portfolio to Include World's Leading Obsessive Compulsive Disorder Measurements

Wednesday, April 14, 2021 - 1:00pm

b'ATLANTA, April 14, 2021 /PRNewswire-PRWeb/ --nView Health, the premier provider of evidence-based behavioral health solutions, is pleased to announce the addition of a series of new products to comprehensively address a series of mental health disorders specific to Obsessive Compulsive Disorder (OCD).

Key Points: 
  • b'ATLANTA, April 14, 2021 /PRNewswire-PRWeb/ --nView Health, the premier provider of evidence-based behavioral health solutions, is pleased to announce the addition of a series of new products to comprehensively address a series of mental health disorders specific to Obsessive Compulsive Disorder (OCD).
  • nView\'s OCD measurements include:\n"The addition of these world-renowned proprietary solutions is exciting and timely given the escalating global mental health crisis," said Dr. Thomas Young, Founder and Chief Medical Officer at nView Health.
  • "This is another large step forward for nView as we grow our digital platform of the world\'s leading behavioral health assessment technologies and make these solutions widely available to our research and healthcare provider customers around the world.
  • Anyone interested in using the OCD measurements or other exclusive nView assessment tools should reach out via our website, nview.com , to learn more about nView solutions and licensing.

Claritycon Mental Health Conference to feature three renowned speakers

Wednesday, March 17, 2021 - 6:00pm

It works with kids and their families to manage mental health conditions ranging from ADHD and anxiety to suicidal ideation, bipolar disorder and/or schizophrenia.

Key Points: 
  • It works with kids and their families to manage mental health conditions ranging from ADHD and anxiety to suicidal ideation, bipolar disorder and/or schizophrenia.
  • Clarity CGC provides professional education and CEUs at Claritycon , its annual children's mental health conferences.
  • Her interests focus on OCD, anxiety disorders, mental health stigma and access to mental health care.
  • In addition, the center serves as a teaching hospital for UT Health San Antonio and Baylor College of Medicine.